Over 50,000 HCPs have started more than 755,000 patients with migraine or episodic cluster headache on Emgality and since December 2019, there have been no new safety updates made to the Prescribing Information1-3
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References
- Emgality. Prescribing information. Lilly USA, LLC.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0175.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0174.